Switching to lamivudine in entecavir-treated patients with undetectable HBV DNA - final results at 96 weeks

BACKGROUND: The aim of this study was to determine the efficacy of entecavir followed by lamivudine in patients with undetectable viral load and normal ALT after initial entecavir treatment. METHODS: This is a 2-year prospective trial of 50 patients treated on entecavir 0.5 mg daily for over 6 months, and had …link_to_OA_fulltextThe 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010), Vienna, Austria, 14-18 April 2010. In Hepatology, 2010, v. 52 suppl. S1, p. 549A, abstract no. 46